CRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
Matthew S. Verosloff(Mammoth Biosciences (United States)), Janice S. Chen(Mammoth Biosciences (United States)), Lior Kreindler(Mammoth Biosciences (United States)), Sarah J. Shapiro(Mammoth Biosciences (United States)), James P. Broughton(Mammoth Biosciences (United States)), Shae A. Hubbell(Mammoth Biosciences (United States)), Deepika Verma(Mammoth Biosciences (United States)), Emma Stanfield(Mammoth Biosciences (United States)), Elizabeth Hawkins(Mammoth Biosciences (United States)), Carley G. Hendriks(Mammoth Biosciences (United States)), Emel Alpay(Mammoth Biosciences (United States)), Benjamin A. Blizard(Mammoth Biosciences (United States)), Sonal Jain(Mammoth Biosciences (United States)), Bridget McKay(Mammoth Biosciences (United States))
Cited by 9
Related Papers
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
|Science|2018|4.4k
CRISPR–Cas12-based detection of SARS-CoV-2
|Nature Biotechnology|2020|2.8k
Programmed DNA destruction by miniature CRISPR-Cas14 enzymes
|Science|2018|1.2k
Enhanced proofreading governs CRISPR–Cas9 targeting accuracy
|Nature|2017|1.2k
Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage
|Science|2016|677